Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement

Cancer Letters

Volumn 265, Issue 1, 2008, Pages 55-66

  Ogino, Hirokazu ^a   Yano, Seiji ^a,b   Kakiuchi, Soji ^c   Yamada, Tadaaki ^a   Ikuta, Kenji ^a   Nakataki, Emiko ^a   Goto, Hisatsugu ^a   Hanibuchi, Masaki ^a   Nishioka, Yasuhiko ^a   Ryan, Anderson ^d   Sone, Saburo ^a,c  

^a Institute of Health Biosciences   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Malignant pleural mesothelioma; RET; Tyrosine kinase inhibitors; Vandetanib; VEGF

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN RET; VANDETANIB; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; GENE REARRANGEMENT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGNOSIS;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; GENE REARRANGEMENT; HUMANS; MALE; MESOTHELIOMA; MICE; MICE, SCID; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PIPERIDINES; PLEURAL NEOPLASMS; PROTO-ONCOGENE PROTEINS C-RET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

MUS;

EID: 43449119495     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.02.018     Document Type: Article

References (38)

1. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
2. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
3. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101 (2004) 13306-13311
4. Ohno R. Treatment of chronic myeloid leukemia with imatinib mesylate. Int. J. Clin. Oncol. 11 (2006) 176-183
5. D'Amato G., Steinert D.M., McAuliffe J.C., and Trent J.C. Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control 12 (2005) 44-56
6. Arighi E., Borrello M.G., and Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 16 (2005) 441-467
7. Takahashi M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev. 12 (2002) 361-373
8. Kodama Y., Asai N., Kawai K., et al. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Sci. 96 (2005) 143-148
9. Mulligan L.M., Kwok J.B.J., Healey C.S., et al. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363 (1993) 458-460
10. Donis-Keller H., Dou S., Chi D., et al. Mutations in the RET protooncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet. 2 (1993) 851-856
11. Hofstra R.M.W., Landsvater R.M., Ceccherini I., et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367 (1994) 375-376
12. Carlson K.M., Dou S., Chi D., et al. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc. Natl. Acad. Sci. USA 91 (1994) 1579-1583
13. Grieco M., Santoro M., Berlingieri M.T., et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60 (1990) 557-563
14. Santoro M., Dathan N.A., Berlingieri M.T., et al. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene 9 (1994) 509-516
15. Takahashi M., Ritz J., and Cooper G.M. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 42 (1985) 581-588
16. Light R.W. Pleural Diseases. fourth ed. (2001), Lippincott Williams & Wilkins, Philadelphia
17. Robinson B.W., and Lake R.A. Advances in malignant mesothelioma. N. Engl. J. Med. 353 (2005) 1591-1603
18. Morinaga K., Kishimoto T., Sakatani M., Akira M., Yokoyama K., and Sera Y. Asbestos-related lung cancer and mesothelioma in Japan. Ind. Health 39 (2001) 65-74
19. Wedge S.R., Ogilvie D.J., Dukes M., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 62 (2002) 4645-4655
20. Ciardiello F., Caputo R., Damiano V., et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin. Cancer Res. 9 (2003) 1546-1556
21. Carlomagno F., Vitagliano D., Guida T., et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 62 (2002) 7284-7290
22. Yano S., Muguruma H., Matsumori Y., et al. Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice. Clin. Cancer Res. 11 (2005) 8789-8798
23. Matsumori Y., Yano S., Goto H., Nakataki E., Wedge S.R., Ryan A.J., and Sone S. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncol. Res. 16 (2006) 15-26
24. Yano S., Matsumori Y., Ikuta K., Ogino H., Doljinsuren T., and Sone S. Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer. Int. J. Clin. Oncol. 11 (2006) 73-81
25. Heymach J.V., Nilsson M., Blumenschein G., Papadimitrakopoulou V., and Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin. Cancer Res. 12 (2006) 4441-4445
26. Nakataki E., Yano S., Matsumori Y., et al. A novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor. Cancer Sci. 97 (2006) 183-191
27. Yokoyama A., Kohno N., Fujino S., et al. Origin of heterogeneity of interleukin-6 (IL-6) levels in malignant pleural effusions. Oncol. Rep. 1 (1994) 507-511
28. Yano S., Shinohara H., Herbst R.S., et al. Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res. 60 (2000) 4959-4967
29. Green L.M., Reade J.L., and Ware C.F. Rapid colometric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines. J. Immunol. Methods 70 (1984) 257-268
30. Yano S., Shinohara H., Herbst R.S., et al. Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells. Am. J. Pathol. 157 (2000) 1893-1903
31. Nikiforov Y.E., Koshoffer A., Nikiforova M., Stringer J., and Fagin J.A. Chromosomal breakpoint positions suggest a direct role for radiation in inducing illegitimate recombination between the ELE1 and RET genes in radiation-induced thyroid carcinomas. Oncogene 18 (1999) 6330-6334
32. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21 (2003) 2636-2644
33. Govindan R., Kratzke R.A., Hernod II J.E., et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin. Cancer Res. 11 (2005) 2300-2304
34. Mathy A., Baas P., Dalesio O., and van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial. Lung Cancer 50 (2005) 83-86
35. Zucali P.A., and Giaccone G. Biology and management of malignant pleural mesothelioma. Eur. J. Cancer 42 (2006) 2706-2714
36. Strizzi L., Catalano A., Vianale G., et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J. Pathol. 193 (2001) 468-475
37. Ferrara N. The role of vascular endothelial growth factor in the regulation of blood vessel growth. In: Bicknell R., Lewis C.E., and Ferrara N. (Eds). Tumor Angiogenesis (1997), Oxford University Press, Inc., New York (185-199)
38. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23 (2005) 1011-1027